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Tissues from 98 human hepatocellular carcinomas
(HCCs) obtained fromhepatic resectionswere subjected
to somatic copy number variation (CNV) analysis. Most
of these HCCs were discovered in livers resected for
orthotopic transplantation, although in a few cases, the
tumors themselves were the reason for the hepatecto-
mies. Genomic analysis revealed deletions and amplifi-
cations in several genes, and clustering analysis based
on CNV revealed five clusters. The LSP1 gene had the
most cases with CNV (46 deletions and 5 amplifica-
tions). High frequencies of CNV were also seen in PT-
PRD (21/98), GNB1L (18/98), KIAA1217 (18/98), RP1-
1777G6.2 (17/98), ETS1 (11/98), RSU1 (10/98),
TBC1D22A (10/98), BAHCC1 (9/98), MAML2 (9/98),
RAB1B (9/98), and YIF1A (9/98). The existing literature
regarding hepatocytes or other cell types has connected
many of these genes to regulation of cytoskeletal archi-
tecture, signaling cascades related to growth regulation,
and transcription factors directly interacting with nu-
clear signaling complexes. Correlations with existing
literature indicate that genomic lesions associated with
HCC at the level of resolution of CNV occur on many
genes associated directly or indirectly with signaling
pathways operating in liver regeneration and hepato-
cyte growth regulation. (Am J Pathol 2012, 180:1495–1508;
DOI: 10.1016/j.ajpath.2011.12.021)
Hepatocellular carcinoma (HCC) is the most common
type of liver cancer and is associated with high mortalityand morbidity. Several chronic conditions are associated
with an increased incidence of HCC, including alcohol-
ism, chronic infections with hepatitis B virus (HBV) or
hepatitis C virus (HCV), hemochromatosis, and metabolic
diseases. Common to all these conditions is that their
chronic forms may cause liver cirrhosis and HCC can
often arise on this background. Because most of the
previously mentioned conditions do not involve genotoxic
agents and none of the associated viruses carry trans-
forming oncogenes, it is reasonable to assume that, for
most HCCs, cirrhosis per se and associated irregularities
induced in the hepatocyte microenvironment are some-
how responsible for generating genomic or epigenetic
alterations leading to carcinogenesis. Cirrhosis is asso-
ciated with a higher rate of hepatocyte proliferation. HCC
in rodents appears, in most conditions, associated with
long-term hyperproliferation of hepatocytes.1 Several
genomic abnormalities have been described in HCC,
such as mutations in p53 and -catenin, deletions in
areas of chromosome 1, and activation of specific onco-
genes by HBV through insertional mutagenesis.2 Genes
expressed by HBV or HCV may cause a long-term pro-
motion effect, also facilitating the evolution of HCC.3
Studies4–6 of gene expression in HCC have demon-
strated subgroups of three clusters with differing gene
expression profiles and prognosis. Despite several stud-
ies related to gene expression profiling of hepatocyte-
derived tumors (adenomas or HCCs), there has been
little analysis of genome-wide alterations underpinning
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AJP April 2012, Vol. 180, No. 4the altered patterns of gene expression.7 We performed
this study to assess genetic alterations (deletions or am-
plifications) detectable by analysis of copy number vari-
ation (CNV) and to examine the relationships, if any, to
the known pathways controlling hepatocyte growth dur-
ing liver regeneration and in hepatocyte cultures.8–14 We
have used the Affymetrix (Santa Clara, CA) 6.0 single-
nucleotide polymorphism (SNP) oligonucleotide arrays
for these studies. The method provides useful information
on the types of deletions and amplifications larger than
approximately 1000 bp and is much more detailed than
studies of large areas of loss of heterozygosity. In addi-
tion, this approach provides detailed information about
the site of the genomic alterations within specific genes,
allowing correlations between the expected changes in
protein structure and the change in function.
Materials and Methods
Case Material
Formalin-fixed, paraffin-embedded (FFPE) tissue speci-
mens were obtained from the Surgical Pathology Ar-
chives of the University of Pittsburgh Medical Center,
Pittsburgh, PA, in accordance with Institutional Review
Board regulations (PRO-08050186). Anonymized sam-
ples spanned a 26-year period, from 1981 through 2006.
This time interval partially antedated establishment of the
Milan criteria15 and spanned a period during which HBV
infection was a more frequent indication for transplanta-
tion at our center.
Clinical information was obtained via Honest Broker
from the EDIT Transplant Database and Surgical Pathol-
ogy records. This included patient survival, tumor size,
tumor recurrence after transplantation, underlying dis-
ease, and -fetoprotein levels. The 98 adult patients in-
cluded 22 females and 76 males. Samples were derived
from native livers at transplantation in all but six patients
who underwent surgical resection. Matched control tis-
sue was obtained from noncirrhotic tissue, usually from
hilar tissue, and did not include lymph nodes. Underlying
diseases included HBV infection (n  22), HCV infection
(n  21), ethanol use (n  13), hemochromatosis (n  3),
and primary sclerosing cholangitis (n  2). Six patients
had multiple underlying disorders (3 HBV and HCV, 2
HCV and ethanol use, and 1 HBV, HCV, and ethanol use),
and one patient each had sarcoid, granulomatous dis-
ease not further specified, type II glycogen storage dis-
ease, autoimmune hepatitis, and nonalcoholic steato-
hepatitis. In 26 patients, there was either no known
underlying disorder or insufficient data to establish an
underlying disease. Tumors were solitary in 30 patients
and multiple in 66 patients. No determination was possi-
ble in the remaining two patients. All tumors were HCCs,
with five representing the fibrolamellar variant. Histologi-
cal grading was performed by one of the authors
(M.A.N.), and tumors were evaluated for the presence of
steatosis, inflammation, giant cells, fibrosis, bile produc-
tion, cytoplasmic inclusions, and Mallory hyaline.Tissue Processing, DNA Extraction, Amplicon
Generation, and Labeling
FFPE tissues were microdissected to achieve tumor pu-
rity 85%. The dissected tissues were incubated in xy-
lene solution overnight to remove residual paraffin. DNA
was then extracted using the Qiagen tissue kit (Qiagen,
Valencia, CA). Amplicons were generated by performing
linear PCR using random 12mers on 2-g DNA templates
using the following program: 94°C for 1 minute and then
40 cycles of 94°C for 30 seconds, 45°C for 1 minute, and
72°C for 2 minutes. The PCR products were then purified
and digested with DNase1 for fragmentation. The frag-
mented DNA was then labeled with biotinylated cytosine.
Hybridization, Washing, and Scanning of the
SNP 6.0 Chip
Fragmented DNA (250 g) was hybridized with a pre-
equilibrated Affymetrix chip at 50°C for 16 hours. After the
hybridization cocktails were removed, the chips were
then washed in a fluidic station with low-stringency buffer
(six times SSPE, 0.01% Tween 20, and 0.005% antifoam)
for 10 cycles (two mixes per cycle) and stringent buffer
(100 mmol/L MES, 0.1 mol/L NaCl, and 0.01% Tween 20)
for 4 cycles (15 mixes per cycle) and then stained with
streptavidin-phycoerythrin. This was followed by incuba-
tion with biotinylated mouse anti-avidin antibody and
restaining with streptavidin-phycoerythrin. The chips
were scanned in a G7 scanner (Affymetrix Inc., Santa
Clara, CA) to detect hybridization signals.
SYBR Green Real-Time Quantitation PCR
The LightCycler FastStart DNA Master SYBR-Green I kit
(Roche Applied Science, Indianapolis, IN) was used for
real-time PCR amplification. The reaction was performed
in a LightCycler machine (Roche Applied Science, Indi-
anapolis, IN). A quantitation standard curve of normal
male DNA from 50,000 to 500,000 copies of genome was
generated using known amounts of template copies.
Genomic DNA (100 ng) was used for all of the experi-
mental and control samples. HotStarTaq DNA polymer-
ase (Qiagen, Valencia, CA) was activated with a 10-
minute pre-incubation step at 95°C. Amplification for
LSP1 (leukocyte-specific protein 1; 5=-CAATGCTCCTC-
TATCCAGCC-3= and 5=-ATGGAGGGGCACTGATTGGA-
3=) and PTPRD (protein tyrosine phosphatase, receptor
type, D; 5=-CGTAGAGATGCCCAGTATCTGC-3= and 5=-
CTCTGATGAGGCTGCCATTGTG-3=) was performed with
45 cycles of the following program: 94°C for 10 seconds,
62°C for 5 seconds, and 72°C for 10 seconds. LightCy-
cler data software version 3.5 (Roche Applied Science)
was used to quantify and fit the data with a standard
curve. A separate -actin DNA quantification was also
performed in parallel with either LSP1 or PTPRD analysis.
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To analyze the data for CNV, CEL files of 196 samples (98
tumor and matched healthy pairs) were imported into
Partek GenomeSuite 6.5 (Partek Inc., St. Louis, MO). De-
termining copy number from the summarized hybridiza-
tion intensities of each tumor sample was accomplished
by normalizing each sample to the matched healthy sam-
ple reference. The genomic segmentation algorithm de-
tects a segmentation according to the following criteria: i)
neighboring regions have statistically significantly differ-
ent average intensities, ii) break points (region boundar-
ies) are chosen to give optimal statistical significance,
and iii) detected regions must contain a user-specified
minimum number of SNPs. To detect regions of deletion
or amplification in the genome, a threshold of a minimum
10 markers (P  0.001) in a region of500 bp is set. The
detected amplification or deletion regions were then
mapped to genome regions where known genes reside.
The changes in copy number are based on an expected
normal number of two. The detail data per case are
shown on Supplemental Table S1 (available at http://
ajp.amjpathol.org). Based on the previously mentioned
criteria, the lowest number above which Partek Genome-
Suite 6.5 was judging for amplification was 2.51 (highest
seen, 12.29). The highest number below which a deletion
was judged was 1.53 (lowest seen, 0.47). The data reflect
the presence of both tumor and healthy cells in the tumor
sample, although microdissection was used to restrict the
presence of nontumor cells to the minimum possible.
Hierarchical Clustering of Cases
Cases were clustered according to 1324 CNV conditions
in the exons or introns of 473 known genes from Partek
preprocessing (see Supplemental Table S1 at http://
ajp.amjpathol.org), ignoring areas that do not contain ex-
pressed genes. We filtered out genes with CNV changes
in 10% (ie, 9) samples. The filtering reduced the data
from 93 samples and 473 genes to 78 samples and 15
genes. The distance measure between two cases was
defined as the reciprocal of a CNV similarity score,
which was calculated as the total number of concor-
dant gene aberrations in two patients. For example, if
two patients have three concordant gene aberrations,
their distance is defined as one third. When two pa-
tients have no concordant gene aberration, the dis-
tance is defined as a large constant (a constant of five
was used herein); varying this constant does not
change the clustering result. Hierarchical clustering
was then performed using average linkage by the
hclust function in R software (http://www.r-project.org).
The testing dependence of two variable Fisher’s exact
tests was used to test the dependence of two variables in
a 2  2 or larger contingency table. For example, it could
be used to test the dependence of patients in clusters
and their deletion in PTPRD or the dependence of LSP1
alteration and tumor size. For comparing continuous ob-
servations in multiple groups (eg, tumor size of patients in
the five clusters), an analysis of variance model and anF-test were used. Both tests were performed using R
software.
Moving-Window Procedure for CNV Histogram
For genomic visualization of CNV regions cumulated
across cases, we used moving windows of 100 kb and
counted the number of cases that contain any CNV re-
gion overlapped with the window. The genome-wide CNV
map was then plotted by R software with chromosomal
locations on the x axis and number of CNV-change pa-
tients on the y axis; amplifications and deletions were
separated by upward blue and downward red colors.
Results
Complete Data from the Study
The data set derived from the CNV determination proce-
dure and subjected to analysis is shown in Supplemental
Table S1 (available at http://ajp.amjpathol.org). The table
provides a complete reference to CNV changes for each
specific gene and each case. There are instructions for
the use of the data set and explanations for the nomen-
clature used to identify individual columns provided in the
table.
Size of the DNA Fragments Used for Analysis
The DNA used for the studies was extracted from FFPE
tissue available in our archives. To investigate the effect
of the fixation and the prolonged embedding in paraffin,
a comparison was made between the length of the DNA
used in our study and DNA extracted from a few freshly
frozen nonfixed HCC samples (Figure 1). There is close
proximity in the frequencies of DNA fragments associ-
ated with the specific lengths, suggesting no demonstra-
ble interference in our studies from the effects of paraffin
Figure 1. Comparison of DNA fragmentation between fresh-frozen and
FFPE tissues. Copy number distribution of frozen sample and its matched
FFPE sample.embedding and fixation.
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Chromosome location of gene Gene symbol CNV cases per gene Amplifications Deletions
11 LSP1 51 5 46
9 PTPRD 21 4 17
22 GNB1L 18 0 18
10 KIAA1217 18 5 13
X RP1-177G6.2 17 4 13
11 ETS1 11 0 11
10 RSU1 10 3 7
22 TBC1D22A 10 2 8
17 BAHCC1 9 0 9
11 CNIH2 9 5 4
11 KLC2 9 5 4
11 MAML2 9 2 7
11 PACS1 9 5 4
11 RAB1B 9 5 4
11 YIF1A 9 5 4
7 ETV1 8 2 6
6 FUCA2 8 2 6
1 NBPF10 8 4 4
16 PDXDC1 8 0 8
8 RNF139 8 0 8
18 BCL2 7 0 7
1 CLCC1 7 0 7
1 PDE4DIP 7 0 7
12 PTPN11 7 3 4
15 ZNF592 7 0 7
1 ABL2 6 0 6
1 CAMTA1 6 0 6
3 ERC2 6 0 6
9 JAK2 6 3 3
7 LHFPL3 6 0 6
1 NBPF1 6 2 4
8 RUNX1T1 6 2 4
10 VIM 6 0 6
5 APC 5 2 3
2 ASB18 5 0 5
19 BBC3 5 0 5
19 CCDC9 5 0 5
X CT45-2 5 3 2
X CT45-4 5 3 2
19 NOTCH3 5 0 5
2 TACR1 5 2 3
8 TATDN1 5 0 5
9 ABL1 4 4 0
12 BICD1 4 0 4
8 DEFB4 4 2 2
5 EPB41L4A 4 2 2
1 FCGR1C 4 4 0
6 GSTA4 4 0 4
1 HFM1 4 0 4
11 JAM3 4 0 4
8 KCNB2 4 4 0
17 KCNH6 4 0 4
8 KCNQ3 4 4 0
15 LOC283755 4 0 4
3 LSAMP 4 0 4
8 MFHAS1 4 0 4
16 MGC34761 4 0 4
11 MPZL3 4 0 4
20 PTPN1 4 0 4
10 RAB11FIP2 4 2 2
1 SELENBP1 4 3 1
17 WDR68 4 0 4
11 ALDH3B2 3 3 0
1 ATG4C 3 0 3
11 CABP2 3 3 0
12 CCDC91 3 0 3
11 CCND1 3 3 0
1 CD48 3 0 3
1 CLK2 3 0 3(table continues)
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Change Frequency
CNV was seen in some genes in more than two cases
(Table 1), demonstrating the total CNV as the sum of the
observed deletions and amplifications. The sum of dele-
tions and amplifications is used as the basis for the rank-
ing, with each of these two types of change also shown in
separate columns. In addition, the type of CNV observed
is provided for each gene and each case. In terms of total
CNV (in 98 cases), amplifications/deletions for the two
top-ranking genes were as follows: LSP1 (51: 5/46) and
PTPRD (21: 4/17). These were followed by GNB1L (18:
0/18), ETS1 (11: 0/11), RSU1 (Ras suppressor 1; 10: 3/7),
TBC1D22A (10: 2/8), BAHCC1 (9: 0/9), CNIH2 (9: 5/4),
KLC2 (9: 5/4),MAML2 (mastermind-like 2; 9: 2/7), PACS1
(9: 5/4), RAB1B (9: 5/4), and YIF1A (9: 5/4). (The
KIAA1217 and RP1-177G6.2 genes will not be discussed,
because they have no known function and are listed as
hypothetical loci in the UniGene database.) Several other
genes directly associated with hepatocyte growth biolog-
ical characteristics also had CNV. These include PTCH1
(Patched-1; 3: 0/3), Ctnnb1 (2: 0/2), KFL6 (2: 0/2), and
EGFR (2: 0/2). The relationship of some of these genes to
the known intracellular signaling cascades associated
Table 1. Continued
Chromosome location of gene Gene symbol
4 CLOCK
19 DPF1
7 DPY19L1
17 ETV4
17 FAM18B2
18 FECH
11 FGF19
9 GABBR2
1 HCN3
7 HOXA10
7 HOXA11
7 HOXA9
1 KHDRBS1
16 KIAA0182
8 KIAA0196
12 LOH12CR1
19 MUC16
19 NFIX
8 NSMCE2
11 ORAOV1
3 PARL
3 PIK3CA
2 PIP5K3
9 PTCH1
7 PTPRN2
12 PWP1
14 RAD51L1
13 RB1
3 SH3BP5
1 SORT1
X SPACA5
X SPACA5B
8 STK3
Y UTYwith hepatocyte growth will be described in Discussion.Chromosomal Localization of CNV Alterations
The deletions and amplifications for each chromosome
are illustrated (Figure 2). The size of the individual bars
shows, on the y axis, the number of cases associated with
the particular CNV. The sites labeled as A (23 cases,
chromosome 9), B (18 cases, chromosome 9), C (52
cases, chromosome 9), D (54 cases, chromosome 10), E
(18 cases, chromosome 14), F (16 cases, chromosome
15), G (17 cases, chromosome 16), and H (39 cases,
chromosome X) are deletions in areas of the chromo-
some containing no known genes. The significance of the
high frequency of deletions in these areas of the genome
with no known gene associations is not clear. The top-
ranked eight genes associated with CNV are also marked
in their chromosomal locations. Three cases are associ-
ated with extensive amplifications in the Y chromosome.
Only the male cases were used to derive the data for the
Y chromosome.
Ideograms demonstrating all of the CNV seen in the
study, regardless of their frequency, on their chromo-
somal locations from male and female cases are pre-
sented (Figure 3, A and B, respectively). Y-chromosome
data were obtained using only male patients. There were
76 CNV cases frommale patients and 22 CNV cases from
female patients. Contiguous areas with deletions are
cases per gene Amplifications Deletions
3 0 3
3 0 3
3 0 3
3 0 3
3 0 3
3 0 3
3 3 0
3 3 0
3 0 3
3 0 3
3 0 3
3 0 3
3 0 3
3 0 3
3 3 0
3 0 3
3 0 3
3 0 3
3 3 0
3 3 0
3 0 3
3 0 3
3 0 3
3 0 3
3 0 3
3 0 3
3 0 3
3 0 3
3 0 3
3 0 3
3 0 3
3 0 3
3 3 0
3 0 3CNVseen in some male cases in chromosomes 4, 10, 12, 20,
ht geno
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chromosomes 1, 8, and 11 (Figure 3A). Overall, there are
no cases with contiguous sites of amplification in female
cases, with cases having contiguous areas of deletion
seen in chromosomes 5, 9, 11, 13, 19, and 22 (Figure
3B). The precise location and frequency (number of
cases) for each deletion and amplification per chromo-
some are shown in Supplemental Table S1 (available at
http://ajp.amjpathol.org).
Figure 2. Localization of deletions and amplifications for each chromosome (
across sample population, we used moving windows of 100 kb and counted th
genome-wide CNV map is plotted with chromosomal locations on the x ax
chromosome (q region)] and number of cases with CNV on the y axis. The
site is illustrated by red (upward) and blue (downward), respectively. The eig
number of deletions are noted.
Figure 3. Ideogram of chromosome deletions or amplifications. Each bar n
detected to have a genome copy number alteration. The frequency of the ev
blue bars, deletions. The chromosome number is indicated at the bottom of e
for male patients were calculated while excluding the female patients, to avoid erro
because the Y chromosome is absent in females.Cluster Analysis and Correlation with Tumor
Attributes
Clustering analysis of 78 cases was based on CNV pres-
ent in exons and introns of known expressed genes,
ignoring CNV in areas that do not contain expressed
genes. Five clear clusters of patients were identified (Fig-
ure 4): clusters A to C mainly contain LSP1 deletions, and
clusters D1 to D2 contain deletions in five genes on
oving-window analysis. For genomic visualization of CNV regions cumulated
er of cases that contained any CNV region overlapping with the window. The
ged from the beginning of the chromosome (p region) to the end of the
of cases (of a total of 98) with amplifications and deletions on the specific
mic locations (A–H) that contain no known genes and that have a significant
he specific chromosome ideogram demonstrates that at least one locus was
ot demonstrated but is shown in Figure 2. Red bars indicate amplifications;
ogram. A: Cases from male patients. B: Cases from female patients. The datachr) by m
e numb
is [arran
numberext to t
ents is n
ach ideneous detection of a deficient amount of Y-chromosome genomic material
not con
enes to
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terized by only an LSP1 deletion. Cluster B contains
cases with deletions in LSP1 plus GNB1L, PTPRD, and
RP1-177G6.2. Cluster C contains a deletion on LSP1 plus
Figure 4. Clustering of the HCC cases based on CNV (amplifications and d
introns of 473 known genes from Partek preprocessing, ignoring areas that do
were filtered out. The filtering reduces the data from 93 samples and 473 gKIAA1217. Clusters D1 and D2 have an amplification or adeletion in five genes (YIF1A, RAB1B, PACS1, CNH2, and
KLC2) on chromosome 11.
We correlated the cluster assignment with tumor attri-
butes using Fisher’s exact test (for discrete attributes) or
). Cases were clustered according to 1324 CNV conditions in the exons or
tain expressed genes. Genes that have CNV changes in10% (or 9) samples
78 samples and 15 genes. For details, see Materials and Methods.eletionsthe F-test from an analysis of variance model (for contin-
correlate
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ure 5). Tested parameters were as follow: sex (P  0.09),
number of tumors (P  0.7), tumor size (cluster C had a
larger tumor size, P 0.043; Figure 5A), survival (clusters
D1  D2 had shorter survival, P  0.056; Figure 5B),
recurrence (P  0.4), presence of Mallory bodies (P 
0.53), fat (cluster B had more fatty inclusions, P 
0.0015; Figure 5C), number of fibrolamellar HCCs
(P  0.09), cytoinclusions (P  0.7), inflammation (P 
0.45), giant cells (P  0.28), fibrosis (P  0.23), and
bile plugs (P  0.89).
Correlations were also seen with some of the attributes
and specific genes as follows: tumor size, MAML2 (P 
0.02); inflammation, ETS1 (P  0.04); presence of fat in
tumor cells, GNB1L (P  0.02) and MAML2 (P 
0.00018); fibrosis, PTPRD (P  0.02); and bile plugs and
cholestasis, RSU1 (P  0.025).
Deletion Mapping for LSP1 and PTPRD
The mapping of the observed deletions in LSP1 and
PTPRD (Figure 6, A and B, respectively) demonstrated
that deletions of LSP1 occur in the C-terminal region,
associated with binding to F-actin filaments.16 The am-
plifications observed also occur in the same region (as
described in Discussion). The deletions seen in PTPRD all
seem to occur in a specific intron site of the gene, toward
the C terminus (as described in Discussion). To validate
the genomic alteration of LSP1 and PTPRD, quantitative
PCR was performed on 21 separate cases of liver cancer
Figure 5. Box plots and a contingency table demonstrate tumor attributes
statistically significant). C: Fatty cell inclusion.with matched healthy tissues. As shown in Table 2, 10 of21 cases showed deletion of LSP1, whereas 2 cases
showed amplification. On the other hand, only 5 of 19
cases showed PTPRD deletion, and 1 case had amplifi-
cation. Of five cases containing PTPRD deletions, four
also contain an LSP1 deletion. The data obtained by
quantitative PCR show CNV change ratios in agreement
with the results obtained by the SNP array.
Genomic Analysis of Regions A to H not
Associated with Known Genes
The data shown in Figure 2 list eight genomic locations (A
to H) that apparently contain no known genes and that
have a significant number of deletions. The data associ-
ated with this analysis are given in detail in Supplemental
Figure S1 (available at http://ajp.amjpathol.org). In sum-
mary, areas upstream and downstream of the deletions
were analyzed for the presence of specific genes, listed
per region. However, further analysis identified the pres-
ence of five motifs present in common in all of these
regions (see Supplemental Figure S2 at http://ajp.
amjpathol.org). In regions A, B, E, F, and G, these motifs
are interspersed. In regions C, D, and H, these motifs are
tightly clustered, suggesting the possibility of a promoter
enhancer region with binding sites for transcription fac-
tors (see Supplemental Figure S3 at http://ajp.amjpathol.
org). Of the eight sites, C, D, and H are associated with
the most cases (51, 53, and 35, respectively). These
areas will be further investigated for the possibility of
controlling regions of genes important in HCC growth
d with cluster assignment. A: Tumor size. B: Log-transformed survival (notdysregulation. Genes associated in proximity to these
sic C-te
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MADD domain containing 1A, LIM homeobox 2; for D,
synaptotagmin XV, G-protein–regulated inducer of neu-
rite outgrowth 2; and for H, high-mobility group box 3 (see
Supplemental Table S2 at http://ajp.amjpathol.org). Gene
ontology analysis for potential associations of the motifs
with genes of different functions was also performed, and
the results indicate a range of possibilities for involve-
ment of these motifs with expression of specific types
with different functions (see Supplemental Table S3 at
http://ajp.amjpathol.org). The chromatin status using the
ENCODE database shows a weak transcription signal for
these areas, as expected (see Supplemental Table S4 at
http://ajp.amjpathol.org).
Discussion
The complete list of affected genes and their distribu-
tion in the 98 cases is shown in Table 1. Overall, 103
genes had more than three CNVs, and the residual 358
genes had only two CNVs. Given that the total number
of genes involved (N  461) is a small fraction of the
genome (estimated at approximately 33,000 genes), we
considered even the presence of the same gene on two
occasions as worthy of mention. In contrast, the involve-
ment of the same gene in four or more cases, given the
Figure 6. Genomic mapping of the deletions (blue) and amplifications (red
The spans of deletions of LSP1 (A) or PTPRD (B) are indicated by a blue line
for detection and P values are indicated. All LSP1 CNVs are located in the ba
between exons 24 and 25.odds from the total gene number, warrants explicit con-sideration as to the biological meaning of the finding in
the context of what is known related to hepatocyte growth
regulation.
Liver regeneration8,9,13 and growth of hepatocytes in
culture17 have been the sources of most information re-
lated to hepatocyte growth regulation. The combination
of these studies has primarily implicated two growth fac-
tor/receptor systems, hepatocyte growth factor (HGF) re-
ceptor (MET) and epidermal growth factor receptor and
all its ligands, primarily epidermal growth factor, trans-
forming growth factor-, and amphiregulin, as the pri-
mary mitogens for hepatocytes.17 Weaker mitogenic ef-
fects have been demonstrated in culture for some ligands
of the fibroblast growth factor receptor family members.18
Many cytokines, however, play important roles in liver
regeneration (less so in hepatocyte cultures) in priming
early stages of the regenerative response. These include
norepinephrine,19–21 TNF,22–24 IL-6,25 bile acids,26 sero-
tonin,27 leptin,28 and Notch1.29,30 The combined effect
of growth factors and cytokines drives hepatocytes into
the cell cycle, resulting in a multiplicity of events within
the first hours after partial hepatectomy and causing
activation of STAT3, NF-B, Notch-dependent genes,
-catenin, and cyclin D1.8,9
With the exception of -catenin (two deletions),
Notch-3 (five deletions), FGF19 (three amplifications),
and PTPRD. Exons are represented by vertical bar; introns, horizontal line.
ications in LSP1 (A) are shown in red. The minimal number of markers used
rminal portion of the resulting protein. Most PTPRD deletions occur in a site) in LSP1
; amplifnone of the previously mentioned genes is directly af-
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tant role in the regulation of hepatocyte growth. On the
other hand, most of the genes involving many cases
identified in this study (Table 1) can be meaningfully and
speculatively correlated with components of internal sig-
naling cascades activated by the previously mentioned
signaling molecules. The potential correlations discussed
later are based on existing published literature about the
functions of these genes in hepatocytes or other cell
types, not on direct experimentation. The results overall
indicate that the primary genetic copy number alterations
associated with the development of liver cancer do not
target the extracellular signals or the initiators of the in-
tracellular signaling pathways known to be driving hepa-
tocyte growth; rather, they affect the molecules in down-
stream signaling pathways. These will be described.
LSP1 Gene
This gene, located on chromosome 11 and not so far
involved in hepatocyte growth biological features, had
the most CNVs (46 deletions and 5 amplifications). LSP1
has been primarily studied in hematopoietic tissues. The
final protein is composed of 339 amino acids, with an
acidic N terminal and a basic C terminal. The latter con-
tains amino acid sequences highly homologous to actin-
binding domains of two F-actin–binding proteins, calde-
smon and the villin headpieces (CI, CII, VI, and VII).16
The C-terminal site binds to F-actin sites and is involved
in mediation of mobility-associated responses in acti-
vated leukocytes.31 Not much is known about binding
Table 2. Genome Copy Numbers of LSP1 and PTPRD in a
Separate Set of HCC Cases, Assessed by Quantitative
PCR
Case no.
LSP1 gene copies
matched T/N*
PTPRD gene copies
matched T/N*
105 0.57/2 1.96/2
107 0.81/2 2.11/2
108 1.08/2 NA
109 2.32/2 4.21/2
111 2.07/2 NA
121 2.25/2 1.84/2
134 4.59/2 2.01/2
138 0.85/2 0.63/2
139 1.09/2 1.04/2
149 1.18/2 2.18/2
151 3.55/2 2.08/2
118 2.06/2 2.16/2
119 2.12/2 2.18/2
144 2.05/2 2.02/2
145 0.76/2 0.46/2
153 0.79/2 1.94/2
163 1.02/2 2.15/2
184 0.89/2 0.41/2
154 0.79/2 0.10/2
157 1.92/2 1.89/2
165 1.95/2 2.21/2
The 21 cases used for assessment of the gene copy numbers of LSP1
and PTPRD were collected from an existing tissue microarray totally
separate from the ones used in this study.
*For each case, T was compared with matched N from the same case.
N, normal tissue; NA, not available; T, tissue from tumor.partners of the N-terminal part. LSP1 is a substrate of p38mitogen-activated protein kinase-activated protein (MAP-
KAP) kinase 2 and protein kinase C.32 Studies in hema-
topoietic cells have shown that LSP1 is a cytoskeletal
targeting protein for the extracellular signal–regulated ki-
nase/mitogen activated protein kinase pathway. The find-
ings suggest a model in which mitogen activated protein
kinase kinase 1 and extracellular signal–regulated kinase
2 are organized in a cytoskeletal signaling complex, to-
gether with kinase suppressor of Ras (KSR), protein ki-
nase C, and LSP1.33 Mice genetically deficient in LSP1
exhibit accelerated healing of skin wounds and in-
creased re-epithelialization rates, collagen synthesis,
and angiogenesis.34 The results suggest that LSP1 plays
an inhibitory role in cell motility, and deletions associated
with loss of function may result in enhanced motility and
migration. LSP1 loss of function may mediate effects
through KSR, a protein directly binding to LSP1.33 KSR
was recently described as a major regulator of cell
growth, because it acts as a scaffold for mitogen-acti-
vated protein kinase, RAF, and mitogen activated protein
kinase.35,36 Of interest, all deletions of LSP1 affect the C
terminal, containing the F–actin binding region (Figure
3A). LSP1 amplifications, however, also affect the same
site. If amplifications were to result in excess production
of a truncated protein containing only the C terminal, this
may have a decoy function, blocking the binding sites on
the F–actin filaments and preventing binding of the full–
length molecule. In other studies, certain polymorphisms
of LSP1 are associated with enhanced probability of
breast cancer development in women who carry germ–
line mutations of the BRCA1 gene.37 We have shown that
integrin-linked kinase (ILK), another protein associated
with the cytoskeleton and controlling function of another
Ras suppressor gene (RSU1, see later), through its part-
ner PINCH, also has growth-suppressing effects on
healthy hepatocytes.38 LSP1 and ILK may constitute a
dual redundant system for control of activity of Ras pro-
teins, thus acting as brakes for hepatocyte growth. Loss
of function of either one should have enhancing effects
on hepatocyte growth. This has been demonstrated for
healthy liver for ILK.38–42
PTPRD Gene
This was the second most affected gene in our study,
with 4 amplifications and 17 deletions. Located on chro-
mosome 14, PTPRD is a known tumor suppressor gene,
with deletions and inactivating mutations in several hu-
man cancers, including lung cancer and glioblasto-
mas.43 Deletions of PTPRD have been shown in rat hep-
atomas and in the human hepatoblastoma HepG2 cell
line.44 Another member of the family, PTPRT, is the most
frequently mutated protein tyrosine phosphatase recep-
tor in human cancer.45 Both PTPRD and PTPRT nega-
tively regulate STAT3.45 The activated form of STAT3 is
phosphorylated in tyrosine sites by janus kinase kinases.
After tyrosine phosphorylation, STAT3 moves to the nu-
cleus, where it functions as a transcription factor and is
involved in enhanced transcription of many cell cycle–
related genes. This has been demonstrated for hepato-
cytes during liver regeneration.46,47 PTPRD (and PTRPT)
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activation and, thus, suppress cell growth. In addition to
the 21 deletions seen in PTPRD, deletions were also
found in the following: PTPN11, four cases (PTPN11 is
associated with Noonan syndrome48); PTPRN2, three
cases; PTPRT, two cases; PTPRCAP, two cases; and
PTPRK, two cases. These findings demonstrate that de-
letions in members of the PTPR family and, especially,
PTPRD contribute to the development of the malignant
phenotype in hepatocytes. Of interest, STAT3 is a major
component of the signaling machinery involved in the
entry of hepatocytes into the S phase during liver regen-
eration.49 The activation of STAT3 is seen within 1 to 3
hours after partial hepatectomy. IL-6 is a major regulator
of the timing of activation of STAT3, and its receptor
(gp130) activates STAT3 via activation of JAK kinases.25
There is a delay in liver regeneration in mice deficient in
IL-6.25 Growth factor receptors (HGF and epidermal
growth factor)50 and the -1 adrenergic receptor51 also
activate STAT3 in a time-delayed fashion in hepatocytes,
and they are likely to take over activation of STAT3 in
IL-6–deficient mice. All 21 deletions observed in our
study occur at an intron site between exons 24 and 25
(Figure 5B).
Ets1 Gene
V-ets erythroblastosis E26 oncogene homolog 1 (Ets1) is
a member of the ETS transcription factor family. These
proteins regulate numerous genes and are involved in
stem cell development, cell senescence and death, and
tumorigenesis.52 The conserved ETS domain is a winged
helix-turn-helix DNA-binding motif that recognizes the
core consensus DNA sequence GGAA/T. There were 11
deletions in the 98 cases (no amplifications) detected in
our study. Ets1 is involved in several malignancies as a
regulator of key progression-linked determinants, such
as osteopontin.53 Most reports relate to overexpression of
Ets1 in tumor cells. It is not clear whether the deletions we
detected would have a gain or loss-of-function effect.
However, Ets1 is a key mediator of the effects of HGF and
its receptor, MET. Many HGF effects on induction of met-
alloproteinases, osteopontin, and angiogenesis are me-
diated by Ets1.54,55 HGF induces expression of Ets1 via
an Ras-dependent pathway.56 Given the key role of HGF
as a major hepatocyte mitogen, the findings related to
Ets1 need to be placed in perspective with the known
studies of HGF related to hepatocyte growth.9
MAML2 Gene
There were seven deletions and two amplifications seen
in this gene. MAML2 and associated family members 1
and 3 participate in the formation of the Notch-associated
RBP-J/CBF complex, which mediates effects of the intra-
cellular domain of Notch after it migrates to the nucleus.57
It is not clear what effect the observed deletions in
MAML2 would have for Notch function. Notch1 is a key
regulator of mitogenic signals at the earliest stages of
liver regeneration. The intracellular domain of Notch mi-
grates to hepatocyte nuclei within 15 minutes after partialhepatectomy and causes expression of the dependent
genes Hes1 and Hes3.30 Inhibition of Notch expression
by silencing RNA in all liver cells is associated with a
blunted regenerative response.30 On the other hand,
germ-line elimination of Notch1 is associated with a dif-
fuse increase in hepatocyte proliferation,29 even though
the regenerative response in these animals is also
blunted. The findings link MAML2 and, thus, Notch, a
regulator of liver regeneration, as a causative contributor
to hepatoma malignant behavior. There is extensive liter-
ature connecting MAML2 with mucoepidermoid carcino-
mas, leukemias, lymphomas, and hidradenomas.58
RSU1 Gene
There were seven deletions and three amplifications seen
in this gene. RSU1 is a protein expressed in most cells. It
has a leucine-rich repeat domain. It causes suppression
of Ras-related functions. RSU1 has suppressive effects
on the growth of cancer cells.59 It binds to the LIM5
domain of the protein PINCH.60 The latter is part of the
complex formed with ILK and Parvin (IPP complex). We
have shown, in recent studies,38 that targeted genetic
loss of ILK in hepatocytes is associated with enhanced
basal levels of hepatocyte proliferation, increased liver
size, and enhanced deposition of extracellular matrix.
Livers with this defect have an enhanced regenerative
response and end up with a significantly increased liver/
body weight ratio at the end of regeneration after partial
hepatectomy.61 Elimination of ILK results in dissociation
of the IPP complex and, potentially, loss of action of
RSU1, which is normally bound to the IPP complex via
PINCH. We have speculated that loss of function of
RSU1, caused by the dissociation of the IPP complex,
may be the reason for the enhanced proliferation of hepa-
tocytes after targeted elimination of ILK.39,40 The dele-
tions in RSU1 found in this study connect this work with
the findings of abnormally enhanced hepatocyte growth
related to targeted ILK removal from hepatocytes. Of
interest, the much more frequent deletions in LSP1 (pre-
viously described) may also involve the similar loss of
KSR (previously described). In fact, six of the seven de-
letions in RSU1 were seen in cases that also had dele-
tions in LSP1.
PTCH1 Gene
This gene expresses the receptor of Hedgehog,
Patched-1, which inhibits Smoothened, a protein associ-
ated with initiation of the signaling cascade of the Hedge-
hog pathway. Hedgehog proteins bind to Patched-1 and
prevent it from inhibiting Smoothened. There were three
deletions associated with PTCH1. Deletions of Patched-1
are likely to relieve Smoothened from inhibition and, thus,
cause continuous activation of the Hedgehog pathway.
There is already emerging literature for a role of Hedge-
hog in regulation of liver regeneration62 and of the growth
of hepatic progenitor cells.63 A recent study64 has also
documented dysregulation of the Hedgehog pathway in
human liver cancer. There is extensive literature65 on the
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cell–nevus syndrome and associated neoplasias.
Other Gene Mutations and Genomic Changes
Several other genes listed in Table 1 are also associated
with regulation of cell growth in epithelial cells, including
hepatocytes. These genes include ABL1, ABL2, Bcl2,
APC, JAK2, CCND1, RB1, and BBC3 (alias PUMA),
among others.9,10 Other genes, such as GNB1L (18 de-
letions), TBC1D22A(two amplifications and eight dele-
tions), BAHCC1 (nine deletions), CNIH2 (five amplifica-
tions and four deletions), and KLC2 (five amplifications
and four deletions), have not been associated with either
HCC or cancer biological characteristics in the litera-
ture.66 These genes need to be further investigated for
their precise role in HCC. Although we see deletions in
several of these genes, it is not clear from our data
whether these deletions result in a loss or gain of function.
There is extensive literature on chromosomal aberra-
tions in HCC. Previous studies67,68 have focused on de-
letions on chromosome 1 (both p and q arms) and am-
plifications in the q region. Our results confirm these
studies. Allelic gains have also been described for chro-
mosome 8q, which are also confirmed from our results
showing extensive amplifications (in males) of multiple
regions in the q arm of chromosome 8.69 Chromosomes
9, 11, and 12 also showed areas of gene amplification
(CNV gains). There were several cases with contiguous
deletions on the Y chromosome (Figures 2 and 3). The
functions of the affected genes are not well understood.
Given the high preponderance of HCC in males versus
females, the functions of these genes in hepatocyte
growth biological features should be investigated.
The clustering of HCC based on CNV of expressed
genes is shown in Figure 4. LSP1 plays a dominant role in
defining the clustering of the cases. Clusters A through C
are mainly associated with LSP1 deletions. Cluster B is
distinguished from A and C by the deletions seen in
PTPRD. Cluster C is associated with deletions in gene
KIAA1217 (a hypothetical locus of unknown function).
Cluster D is composed of two parts. Genes YIF1A,
RAB1B, PACS1,CNIH2, and KLC2 bear amplifications in
cluster 4A and deletions in cluster 4B. CNVs undoubtedly
are acting in concert with other genomic changes of
smaller size (eg, mutations, such as in -catenin63 or
p5370) to contribute to HCC behavior. Recent studies71
with rodent livers have also demonstrated that hepato-
cytes become spontaneously aneuploid at a high fre-
quency with increasing age of the animals. It is not clear
whether this occurs in human hepatocytes.
Because the time from resection of the tissue samples
used in this study spans a wide spectrum, we addressed
the possibility of artifacts that should be considered for
FFPE material. DNA fragmentation is often seen in FFPE
tissue samples. In Figure 1, the distribution of the size of
DNA fragments seen in a fresh-frozen HCC versus that of
an FFPE sample is almost indistinguishable. In Supple-
mental Table S1 (available at http://ajp.amjpathol.org), the
range of the size of deletions is from 32,854,362 to 535
bp. The method applied for detection of CNV is per-formed by comparison of the tumor samples with the
DNA of the corresponding healthy tissues. Thus, it is
unlikely that larger deletions, if present in our sample
size, would have been missed due to DNA fragmentation,
because fragmentation does not occur on a deleted area
(physically paradoxical) but rather on existing DNA frag-
ments. If larger deletions existed in our samples, the
method applied would have reported them as such.
Concluding Remarks
The absence of a strong correlation of CNV alterations
with many specific tumor parameters, such as multiplic-
ity, histological variables, and survival, in this series is not
totally unexpected for several reasons. First, the pres-
ence of a few cases with no evidence of CNV suggests
that full tumor development may occur in the complete
absence of such changes. Our retrospective series is
limited in number, is restricted to a single transplantation
center, and spans several decades during which clinical
practice evolved considerably. Therefore, it would be
unlikely that correlation with any single CNV subset would
be of sufficient strength to emerge as a dominant predic-
tor of tumor behavior. Rather, the results indicate the
need for integrating such studies with other modalities of
tumor cell genomic analysis in many patients to construct
a comprehensive roadmap of the multiplicity of pathways
leading to HCC pathogenesis. On the other hand, stud-
ies6,72 of the patterns of gene expression of HCC have
shown clustering into two to three overall patterns. The
combined studies suggest that alignments of multiple
genomic alterations may activate one of the two to three
specific gene expression patterns and that neoplastic
behavior of the affected hepatocytes ensues once such
threshold change has been achieved. Also, we did not
observe any correlation between the genomic alterations
observed and the associated etiology that led to the
cirrhosis pattern that caused liver resection, including
alcoholic liver disease and viral causes. A similar lack of
correlations has been noted with such potentially asso-
ciated pathogenetic factors and the associated gene ex-
pression pattern of HCC in previous studies.
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